Atenas

**Atenas** is an oral fixed-dose combination product being developed by **EMS** for patients with **type 2 diabetes mellitus and hypertension**. Public trial records identify Atenas as the combination of **empagliflozin, telmisartan, and amlodipine** in a Phase III randomized, double-blind, triple-dummy study. Mechanistically, it combines an **SGLT2 inhibitor** to lower glucose via increased urinary glucose excretion with an **angiotensin II type 1 receptor blocker** and a **dihydropyridine calcium channel blocker** to reduce blood pressure. The asset appears to be positioned as a single-pill oral cardiometabolic combination intended for patients who require treatment of both hyperglycemia and hypertension.

Brand names

Atenas

Other names

Atenasempagliflozin + telmisartan + amlodipine